Exelixis, Inc. (EXEL)

Over the past six months, Exelixis's stock price has been influenced by several events. In Q2 2025, Exelixis reported adjusted earnings of 75 cents per share, surpassing estimates, but sales fell short due to lower collaboration revenues. The company has been actively repurchasing its common stock with an ongoing $500 million program and an additional $500 million program authorized in February 2025. Analyst activity included two downgrades and one upgrade, with Zacks Research upgrading Exelixis on February 6, 2026. There has been significant insider selling of Exelixis stock. The FDA accepted Exelixis's New Drug Application for zanzalintinib for metastatic colorectal cancer. As of February 5, 2026, the stock had decreased by 3.00% in the past month but had increased by 25.84% over the last 12 months.

Based on available information, there is no explicit indication of significant demand seasonality for Exelixis's products and services. The company's Cabozantinib franchise has shown consistent year-over-year growth in demand and revenue, suggesting a relatively stable and growing demand rather than pronounced seasonal fluctuations.

Exelixis, Inc. is an oncology-focused biotechnology company dedicated to discovering, developing, and commercializing novel therapies for difficult-to-treat cancers. Its major approved products include Cabometyx® (cabozantinib tablets) and Cometriq® (cabozantinib capsules), used for advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer, respectively. Exelixis also markets Cotellic® for melanoma in partnership with Roche and is advancing its pipeline with zanzalintinib, a promising new drug with its NDA accepted by the FDA for metastatic colorectal cancer.

Exelixis primarily focuses on the discovery, development, and commercialization of its medicines in the United States. It extends its reach beyond the U.S. through licensing agreements, providing other companies with the rights to sell its drugs and earning royalty income from these partnerships.

Exelixis maintains a generally positive brand reputation within the oncology and biotechnology sectors, primarily driven by the success of Cabometyx and advancements in its pipeline. The company's commitment to developing treatments for difficult-to-treat cancers contributes to its standing. The FDA's acceptance of the New Drug Application for zanzalintinib further enhances its reputation as an innovative oncology company.

Exelixis, Inc. has a diverse ownership structure. Institutional investors hold a significant portion of the company's stock, with approximately 1222 institutional owners holding a total of 303,173,549 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Farallon Capital Management Llc, Renaissance Technologies Llc, and State Street Corp. As of January 2026, institutional investors held 96.44% of the shares, while insiders held 2.26%. Another source indicates that approximately 24.57% of the company's stock is owned by Institutional Investors, 3.72% by Insiders, and 28.92% by Public Companies and Individual Investors.